Eagle Pharmaceuticals, Inc.
OTCPK:EGRX Stok Raporu
Eagle Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 1/6 Eagle Pharmaceuticals şirketinin kazançları yıllık ortalama -47.6% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 5.4% oranında azalan oldu. Eagle Pharmaceuticals şirketinin öz sermaye getirisi 4.7% olup, net marjı 4.6% dir.
Anahtar bilgiler
-47.6%
Kazanç büyüme oranı
Biotechs Sektör Büyümesi 17.0% Gelir büyüme oranı -5.4% Özkaynak getirisi 4.7% Net Marj 4.6% Son Kazanç Güncellemesi 30 Jun 2023
Yakın geçmiş performans güncellemeleri
Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 10
Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 09
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 08
Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 14
Tüm güncellemeleri göster
Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes Nov 12 Hearings Panel of The Nasdaq Stock Market LLC Determines to Delist Eagle Pharmaceuticals' Common Stock from Nasdaq Oct 04
Eagle Pharmaceuticals, Inc.(OTCPK:EGRX) dropped from NASDAQ Composite Index
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq Aug 28 Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing Aug 10
Eagle Pharmaceuticals, Inc. and Curia Global, Inc. Enters into Settlement Agreement in AAA Case No. 01-23-0000-2937 Jul 10 Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq May 23 Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing May 12
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K Apr 13 Eagle Pharmaceuticals, Inc. announced delayed annual 10-K filing Mar 19
Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes
New minor risk - Financial data availability Feb 24
Investor sentiment improves as stock rises 19% Feb 21
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc Dec 12 Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer
Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing Nov 11
Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 10
Investor sentiment deteriorates as stock falls 32% Nov 10
Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 09
Founder notifies of intention to sell stock Nov 03
Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc Oct 24
Founder notifies of intention to sell stock Oct 04
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment? Sep 21
Investor sentiment deteriorates as stock falls 18% Aug 15
New major risk - Revenue and earnings growth Aug 09
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 08
Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Eagle Pharmaceuticals, Inc. Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, A Novel First-In-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia Jul 25
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Jul 13
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Growth-Defensive Index Jun 25
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly Jun 21
New major risk - Revenue and earnings growth Jun 17
Eagle Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (Qidp) and Fast-Track Designation for Cal02, Providing Five-Year Exclusivity Extension Jun 15
Founder recently sold US$931k worth of stock May 17
Founder notifies of intention to sell stock May 15
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 14
Consensus EPS estimates fall by 20% Jan 25
Eagle Pharmaceuticals, Inc. Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy Dec 20
Consensus forecasts updated Nov 23
Insufficient new directors Nov 16
Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia Nov 15
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 08
Eagle Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Nov 01
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely Oct 27
Eagle Pharmaceuticals, Inc Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02 Oct 14
Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia Oct 12
Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose Sep 27
Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders. Sep 17
Independent Director recently sold US$211k worth of stock Sep 09
Insufficient new directors Sep 02
U.S. Court of Appeals for the Federal Circuit Affirms the U.S. District Court for the District of Delaware’s Decision That Eagle Pharmaceuticals, Inc.'s Vasopressin Product Does Not Infringe on Any of the Patents Asserted by Par Pharmaceutical, Inc Aug 19
Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court Aug 18
Consensus revenue estimates fall by 21% Aug 16
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be Aug 15
Price target decreased to US$43.00 Aug 10
Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M Aug 09
Eagle Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 29 Michael Moran Separates as Executive Vice President, Chief Commercial Officer of Eagle Pharmaceuticals, Inc
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely Jul 06
Eagle Pharmaceuticals, Inc., Annual General Meeting, Jul 28, 2022 Jun 16
Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders. Jun 10
Eagle Pharmaceuticals, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, A Beta-1 Adrenergic Blocker Jun 02
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 10
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price Apr 29
Now 20% undervalued Apr 19
Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders for €89.8 million. Mar 30
Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH). Mar 29
Eagle Pharmaceuticals, Inc. Provides Earnings Guidance for the First Quarter of 2022 Mar 10
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 09
Eagle Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 07, 2022 Feb 25
Eagle Pharmaceuticals, Inc. Announces Commercial Availability of PEMFEXY™ Feb 02
Eagle Pharmaceuticals, Inc. on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker Feb 01
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin Jan 19
Eagle Pharmaceuticals, Inc. Receives 180 Days of Marketing Exclusivity for Approved Vasopressin Dec 30
Eagle Pharmaceuticals, Inc. Receives FDA Approval for Vasopressin Dec 16
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt? Dec 16
Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.52 profit in 3Q 2020) Nov 11
Price target increased to US$50.50 Nov 11
Eagle Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi OTCPK:EGRX Gelir, gider ve kazançlar (USD Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 30 Jun 23 258 12 103 36 31 Mar 23 267 -3 93 37 31 Dec 22 317 36 87 34 30 Sep 22 298 21 82 31 30 Jun 22 272 23 79 45 31 Mar 22 246 36 78 43 31 Dec 21 172 -9 75 51 30 Sep 21 179 6 76 57 30 Jun 21 189 18 75 38 31 Mar 21 183 14 76 36 31 Dec 20 188 12 79 31 30 Sep 20 186 5 80 33 30 Jun 20 177 -5 81 38 31 Mar 20 192 2 80 40 31 Dec 19 196 14 76 37 30 Sep 19 204 26 69 31 30 Jun 19 214 42 65 27 31 Mar 19 216 38 63 33 31 Dec 18 213 32 61 44 30 Sep 18 204 28 58 48 30 Jun 18 216 30 61 51 31 Mar 18 207 32 68 42 31 Dec 17 237 52 71 33 30 Sep 17 271 100 77 38 30 Jun 17 246 97 71 33 31 Mar 17 237 105 60 30 31 Dec 16 189 81 53 28 30 Sep 16 127 25 40 22 30 Jun 16 94 3 35 25 31 Mar 16 60 -18 28 27 31 Dec 15 66 3 20 28 30 Sep 15 54 -4 19 23 30 Jun 15 51 -3 17 22 31 Mar 15 51 2 14 21 31 Dec 14 20 -21 12 19 30 Sep 14 19 -20 9 17 30 Jun 14 17 -11 4 14 31 Mar 14 20 -9 3 11 31 Dec 13 18 -11 4 10
Kaliteli Kazançlar: EGRX yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: EGRX 'nin mevcut net kar marjları (4.6%) geçen yılın (8.4%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: EGRX 'un son 5 yılda yıllık kazanç büyüme oranının pozitif olup olmadığını belirlemek için yeterli veri yok.
Büyüme Hızlandırma: EGRX 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.
Kazançlar vs. Sektör: EGRX geçtiğimiz yıl negatif kazanç büyümesine ( -47.6% ) sahipti ve bu da onu Biotechs sektör ortalamasıyla ( 16.6% ) karşılaştırmayı zorlaştırıyordu.
Özkaynak Getirisi
Yüksek ROE: EGRX 'nin Özsermaye Getirisi ( 4.7% ) düşük olarak değerlendiriliyor.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
